Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
%20POETYK%20PSO-1%20trial_page-0001.jpg)
%20POETYK%20PSO-1%20trial_page-0002.jpg)
%20POETYK%20PSO-1%20trial_page-0003.jpg)
%20POETYK%20PSO-1%20trial_page-0004.jpg)
%20POETYK%20PSO-1%20trial_page-0005.jpg)
%20POETYK%20PSO-1%20trial_page-0006.jpg)
%20POETYK%20PSO-1%20trial_page-0007.jpg)
%20POETYK%20PSO-1%20trial_page-0008.jpg)
%20POETYK%20PSO-1%20trial_page-0009.jpg)
%20POETYK%20PSO-1%20trial_page-0010.jpg)
%20POETYK%20PSO-1%20trial_page-0011.jpg)
%20POETYK%20PSO-2%20trial.pdf_page-0001.jpg)
